Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Unaudited Condensed Interim Consolidated Statements of Shareholders' Equity and Deficit

v3.20.2
Unaudited Condensed Interim Consolidated Statements of Shareholders' Equity and Deficit - USD ($)
Share Capital [Member]
Contributed Surplus [Member]
Net Income (Deficit) [Member]
Total
Beginning balance at Dec. 31, 2018 $ 170,502,394 $ 6,652,409 $ (172,937,694) $ 4,217,109
Beginning balance, share at Dec. 31, 2018 21,675,849      
Statement Line Items [Line Items]        
Issued pursuant to agency agreement $ 16,717,131     16,717,131
Issued pursuant to agency agreement, shares 10,873,044      
Share issue expense $ (1,915,612)     (1,915,612)
Warrants exercised during the period $ 7,002,043     7,002,043
Warrants exercised during the period, shares 1,018,506      
Stock based compensation   1,404,363   1,404,363
Net and comprehensive loss     (44,319,942) (44,319,942)
Ending balance at Sep. 30, 2019 $ 192,305,956 8,056,772 (217,257,636) (16,894,908)
Ending balance, shares at Sep. 30, 2019 33,567,399      
Beginning balance at Dec. 31, 2019 $ 194,859,415 8,303,527 (214,844,773) $ (11,681,831)
Beginning balance, share at Dec. 31, 2019 39,907,681     39,907,681
Statement Line Items [Line Items]        
Issued pursuant to agency agreement [1] $ 12,818,657     $ 12,818,657
Issued pursuant to agency agreement, shares [1] 23,923,700      
Share issue expense $ (487,788)     (487,788)
Common stock equivalents converted $ 1,150     1,150
Common stock equivalents converted, shares 11,500,000      
Warrants exercised during the period $ 5,900,087     5,900,087
Warrants exercised during the period, shares 6,217,939      
Stock based compensation   720,774   720,774
Net and comprehensive loss     (3,551,875) (3,551,875)
Ending balance at Sep. 30, 2020 $ 213,091,521 $ 9,024,301 $ (218,396,648) $ 3,719,174
Ending balance, shares at Sep. 30, 2020 81,549,320     81,549,320
[1] Includes net proceeds from the issuance of common share equivalents (see note 9a).